The Journal of Practical Medicine >

2025 , Vol. 41 >Issue 2: 238 - 243

DOI: https://doi.org/10.3969/j.issn.1006-5725.2025.02.013

Clinical Research

Correlation between plasma ADAMTS13 level， disease severity and prognosis in patients with endometriosis

  • Ke XU ,
  • Mingzhe ZHANG ,
  • Mingyang WANG ,
  • Song. LIU
Expand
  • *.Department of Gynecology，Affiliated Hospital of Zunyi Medical University，Zunyi 563003，Guizhou，China

Received date: 2024-10-18

  Online published: 2025-01-26

Fold

Abstract

Objective To investigate the relationship between plasma von willebrand factory-lytic protease （ADAMTS13） level and the severity of the disease and its prognostic value in patients with endometriosis （EMS）. Methods 130 patients with EMS treated in the hospital from January 2019 to December 2022 were retrospectively selected. Plasma ADAMTS13 level was detected by enzyme-linked immunosorbent assay （ELISA）， and its correlation with American Fertility Society （r-AFS） stage and endometriosis Health Status Scale （EHP-30） score was analyzed. The 1-year prognosis was recorded， and the risk factors of poor prognosis were analyzed by logistic regression. Receiver operating characteristic curve （ROC） was plotted to evaluate the predictive value of plasma ADAMTS13 levels in patients with EMS. Results The plasma ADAMTS13 level of EMS patients decreased significantly with the increase of r-AFS stage， and was negatively correlated with the score of EHP-30 （P < 0.001）. Multiple factors showed that low plasma ADAMTS13 level， bilateral location of pelvic lesions and high r-AFS stage were independent risk factors for poor prognosis （all P < 0.05）. ROC analysis showed that the area under the curve （AUC） of plasma ADAMTS13 was 0.889 （cut-off point 13.315， sensitivity 0.931， specificity 0.690）. Conclusion Plasma ADAMTS13 level is negatively correlated with the severity of EMS， and is an independent risk factor for poor prognosis of EMS patients， and has a certain predictive value for prognosis of EMS patients.

Key words： endometriosis; plasma ADAMTS13 level; r-AFS staging; prognosis

Cite this article

Ke XU , Mingzhe ZHANG , Mingyang WANG , Song. LIU . Correlation between plasma ADAMTS13 level， disease severity and prognosis in patients with endometriosis[J]. The Journal of Practical Medicine, 2025 , 41(2) : 238 -243 . DOI: 10.3969/j.issn.1006-5725.2025.02.013

References

1 杨如玉，梁炎春，韦雅婧，等. 缺氧诱导HIF?1α在子宫内膜异位症巨噬细胞极化异常的作用及机制研究［J］. 实用医学杂志，2022，38（8）：964-969.
2 吴玉良，吴春玲，吴丹. 血清sFLT1、CTRP3水平与子宫内膜异位症的相关性［J］. 实用医学杂志，2023，39（14）：1798-1803.
3 MONTANARI E， REH L M， DAUSER B， et al. Serial assessment of inflammatory parameters for prediction of septic complications following surgery for colorectal endometriosis［J］. Wien Klin Wochenschr， 2022， 134（3-4）：118-124. doi:10.1007/s00508-021-01916-w
4 KAI K， JOSHI N R， BURNS G W， et al. MicroRNA-210-3p Regulates Endometriotic Lesion Development by Targeting IGFBP3 in Baboons and Women with Endometriosis ［J］. Reprod Sci， 2023， 30（10）：2932-2944. doi:10.1007/s43032-023-01253-5
5 ZHAO X， LI X， LIU P， et al. 17β-estradiol promotes angiogenesis through non-genomic activation of Smad1 signaling in endometriosis［J］. Vascul Pharmacol， 2022， 142：106932. doi:10.1016/j.vph.2021.106932
6 TIAN W， LIU M， LIU Y， et al. TIM-3 regulates the proliferation by BDNF-mediated PI3K/AKT axis in the process of endometriosis［J］. Mol Med， 2023， 29（1）：170. doi:10.1186/s10020-023-00768-6
7 LIU F， ZHOU J， ZHANG X， et al. Whole-exome sequencing and functional validation reveal a rare missense variant in MMP7 that confers ovarian endometriosis risk［J］. Hum Mol Genet， 2022， 31（15）：2595-2605. doi:10.1093/hmg/ddac062
8 HALKIDIS K， ZHENG X L. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura［J］. J Thromb Haemost， 2022， 20（10）：2197-2203. doi:10.1111/jth.15822
9 BONNEZ Q， SAKAI K， VANHOORELBEKE K. ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura［J］. J Clin Med， 2023， 12（19）：6169. doi:10.3390/jcm12196169
10 LI Y， LIU H， YE S， et al. The effects of coagulation factors on the risk of endometriosis： A Mendelian randomization study［J］.BMC Med， 2023， 21（1）：195. doi:10.1186/s12916-023-02881-z
11 中华医学会妇产科学分会子宫内膜异位症协作组. 子宫内膜异位症的诊治指南［J］. 中华妇产科杂志，2015，50（3）：161-169.
12 SOCIETY A F. Revised classification of endometriosis［J］. Fertil Steril， 1979， 43（43）：351-352.
13 JENKINSON C， KENNEDY S， JONES K G. Evaluation of the American version of the 30-item Endometriosis Health Profile （EHP-30）［J］. Qual Life Res， 2008， 17（9）：1147-1152. doi:10.1007/s11136-008-9403-9
14 VERCELLINI P， VIGANò P， BANDINI V， et al. Association of endometriosis and adenomyosis with pregnancy and infertility［J］. Fertil Steril， 2023， 119（5）：727-740. doi:10.1016/j.fertnstert.2023.03.018
15 LI P S， PENG X M， NIU X X， et al. Efficacy of acupuncture for endometriosis-associated pain： A multicenter randomized single-blind placebo-controlled trial［J］. Fertil Steril， 2023， 119（5）：815-823. doi:10.1016/j.fertnstert.2023.01.034
16 MADARATI H， SINGH K， SPARRING T， et al. Reviewing the dysregulation of adamts13 and vwf in sepsis［J］. Shock， 2024， 61（2）：189-196. doi:10.1097/shk.0000000000002291
17 KHALIQUE S， NASH S， NATRAJAN R. Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis-related ovarian cancers［J］.J Pathol， 2022， 258（1）：1-3. doi:10.1002/path.5973
18 ZHU T， DU Y， JIN B. Identifying Immune Cell Infiltration and Hub Genes Related to M2 Macrophages in Endometriosis by Bioinformatics Analysis［J］. Reprod Sci， 2023， 30（11）：3388-3399. doi:10.1007/s43032-023-01227-7
19 VIVIANO M， BENAGIANO G， GUO S W， et al. Why do oestrogens matter： Systematic review and meta-analysis assessing GnRH antagonists， considering add-back therapy， for endometriosis-associated pain［J］.Reprod Biomed Online， 2024， 49（4）：104321. doi:10.1016/j.rbmo.2024.104321
20 黄春芝， 刘青蓝， 苏冉， 等. 青少年子宫内膜异位症药物治疗选择及药物治疗进展［J］. 中国临床药理学与治疗学， 2024， 29（5）： 535-542.
21 ZHANG J， DONG L， ZHANG S， et al. Analysis of the clinical efficacy of leuprolide acetate in the treatment of obese patients with endometriosis and its role on the expression of MIF gene［J］. Cell Mol Biol （Noisy-le-grand）， 2022， 67（4）：282-288. doi:10.14715/cmb/2021.67.4.31
22 POHL O， BARON K， RIGGS M， et al. A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis［J］. Br J Clin Pharmacol， 2022， 88（5）：2359-2371. doi:10.1111/bcp.15171
23 GIOIA S， CARNEVALE R， TAVANO D， et al. Association between gut‐derived endotoxins and porto‐sinusoidal vascular disorder with portal hypertension［J］. Aliment Pharmacol Ther， 2023， 58（11-12）：1205-1216. doi:10.1111/apt.17727
24 WANG Y， LI W， HA C. A large-scale causal analysis of gut microbiota and endometriosis associated infertility： A Mendelian randomization study［J］. Medicine （Baltimore）， 2024， 103（12）：e37383. doi:10.1097/md.0000000000037383
25 PAN Y， WU T， SHI H. Distinct clinicopathological features of ovarian endometriosis after long-term exposure to mifepristone［J］.J Int Med Res， 2022， 50（11）：3000605221134471. doi:10.1177/03000605221134471
26 HOLDSWORTH-CARSON S J， CHUNG J， MACHALEK D A， et al. Predicting disease recurrence in patients with endometriosis： An observational study［J］. BMC Med， 2024， 22（1）：320. doi:10.1186/s12916-024-03508-7
Options
Outlines

/

〈 〉